Table 2.
Efficacy responses at week 12 and week 52
| Endpoint, patients, % achieving response | North American subgroup | Non-North American subgroup | ||
|---|---|---|---|---|
| Secukinumab 300 mg | Secukinumab 150 mg | Secukinumab 300 mg | Secukinumab 150 mg | |
| Week 12 | ||||
| IGA 0/1 | 76.0 | 49.0 | 66.2 | 57.7 |
| IGA 0 | 41.2 | 14.3 | 28.1 | 17.2 |
| PASI 75 | 85.7 | 68.7 | 82.9 | 75.3 |
| PASI 90 | 66.1 | 33.7 | 56.9 | 47.6 |
| PASI 100 | 37.6 | 13.6 | 25.5 | 15.5 |
| Week 52 | ||||
| IGA 0/1 | 67.7 | 43.1 | 73.1 | 57.7 |
| IGA 0 | 39.8 | 18.0 | 41.4 | 27.0 |
| PASI 75 | 81.2 | 56.3 | 86.9 | 77.0 |
| PASI 90 | 62.9 | 30.9 | 70.2 | 53.9 |
| PASI 100 | 37.9 | 17.5 | 42.0 | 26.9 |
Number of evaluable patients in NA population: secukinumab 300 mg (n = 201 for both IGA and PASI), secukinumab 150 mg (n = 191 for IGA and n = 190 for PASI)
Number of evaluable patients in non-NA population: secukinumab 300 mg (n = 485 for both IGA and PASI), secukinumab 150 mg (n = 499 for IGA and PASI)
IGA (mod 2011) 0/1 Investigator’s Global Assessment, 2011 modified version, improvement to scores of 0 or 1 (clear or almost clear skin), NA North American, PASI 75/90/100 Psoriasis Area and Severity Index 75%/90%/100% improvement from baseline in Psoriasis Area and Severity Index